{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:27:18Z","timestamp":1788964038518,"version":"build-2803163510"},"reference-count":68,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Histone deacetylase inhibitors (HDACis) are antitumor agents with distinct efficacy in hematologic tumors. Pracinostat is a pan-HDACi with promising early clinical activity. However, similar to other HDACis, its activity as a single agent is limited. Diffuse large B-cell lymphoma (DLBCL) includes distinct molecular subsets or metabolically defined subtypes that rely in different ways on the B-cell receptor signaling pathway, oxidative phosphorylation, and glycolysis for their survival. The antitumor activity of pracinostat has not been determined in lymphomas. We performed preclinical in vitro activity screening of 60 lymphoma cell lines that included 25 DLBCLs. DLBCL cells belonging to distinct metabolic subtypes were treated with HDACis for 6 hours or 14 days followed by transcriptional profiling. DLBCL xenograft models enabled assessment of the in vivo antilymphoma activity of pracinostat. Combination treatments with pracinostat plus 10 other antilymphoma agents were performed. Western blot was used to assess acetylation levels of histone and nonhistone proteins after HDACi treatment. Robust antiproliferative activity was observed across all lymphoma histotypes represented. Focusing on DLBCL, we identified a low-sensitivity subset that almost exclusively consists of the oxidative phosphorylation (OxPhos)-DLBCL metabolic subtype. OxPhos-DLBCL cells also showed poorer sensitivity to other HDACis, including vorinostat. Transcriptomic analysis revealed fewer modulated transcripts but an enrichment of antioxidant pathway genes after HDACi treatment of OxPhos-DLBCLs compared with high-sensitivity B-cell receptor (BCR)\u2013DLBCLs. Pharmacologic inhibition of antioxidant production rescued sensitivity of OxPhos-DLBCLs to pracinostat whereas BCR-DLBCLs were unaffected. Our study provides novel insights into the antilymphoma activity of pracinostat and identifies a differential response of DLBCL metabolic subtypes to HDACis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003566","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T15:34:10Z","timestamp":1621265650000},"page":"2467-2480","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-3689","authenticated-orcid":false,"given":"Afua Adjeiwaa","family":"Mensah","sequence":"first","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-1568","authenticated-orcid":false,"given":"Filippo","family":"Spriano","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6704-9755","authenticated-orcid":false,"given":"Giulio","family":"Sartori","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-0026","authenticated-orcid":false,"given":"Valdemar","family":"Priebe","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4606-0637","authenticated-orcid":false,"given":"Luciano","family":"Cascione","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"},{"name":"Swiss Institute of Bioinformatics, Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-7742","authenticated-orcid":false,"given":"Chiara","family":"Tarantelli","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Civanelli","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7893-1740","authenticated-orcid":false,"given":"Luca","family":"Aresu","sequence":"additional","affiliation":[{"name":"Department of Veterinary Science, University of Turin, Grugliasco, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3234-0563","authenticated-orcid":false,"given":"Andrea","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9749-434X","authenticated-orcid":false,"given":"Giovanna","family":"Damia","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS\u2013Istituto di Ricerche Farmacologiche \u201cMario Negri,\u201d Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Lovati","sequence":"additional","affiliation":[{"name":"Helsinn Healthcare, Lugano, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-6109","authenticated-orcid":false,"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"},{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and"},{"name":"Faculty of Biomedical Sciences, USI, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pietra","sequence":"additional","affiliation":[{"name":"Helsinn Healthcare, Lugano, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-8983","authenticated-orcid":false,"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[{"name":"Institute of Oncology Research, Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Bellinzona, Switzerland;"},{"name":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"issue":"11","key":"2021051715324302100_B1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.yexcr.2012.01.025","article-title":"HDAC modulation and cell death in the clinic","volume":"318","author":"Dell\u2019Aversana","year":"2012","journal-title":"Exp Cell Res"},{"issue":"7","key":"2021051715324302100_B2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic therapies for cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"2021051715324302100_B3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"2021051715324302100_B4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","article-title":"Emerging epigenetic-modulating therapies in lymphoma","volume":"16","author":"Sermer","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2021051715324302100_B5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","article-title":"Targeting histone deacetylases in T-cell lymphoma","volume":"58","author":"Moskowitz","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2021051715324302100_B6","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1038\/s41467-019-11046-7","article-title":"Chemical genomics reveals histone deacetylases are required for core regulatory transcription","volume":"10","author":"Gryder","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"2021051715324302100_B7","doi-asserted-by":"crossref","first-page":"e79502","DOI":"10.1371\/journal.pone.0079502","article-title":"The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines","volume":"8","author":"Klein","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2021051715324302100_B8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","article-title":"Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma","volume":"147","author":"Dickinson","year":"2009","journal-title":"Br J Haematol"},{"issue":"18","key":"2021051715324302100_B9","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"2021051715324302100_B10","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2011-01-331421","article-title":"The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines","volume":"119","author":"Lemoine","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2021051715324302100_B11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/10428194.2017.1359741","article-title":"Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma","volume":"59","author":"Hu","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"2021051715324302100_B12","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","article-title":"HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL","volume":"118","author":"Kalac","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2021051715324302100_B13","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.18632\/oncotarget.3239","article-title":"Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response","volume":"6","author":"Mensah","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"2021051715324302100_B14","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2013-02-485441","article-title":"Sirtuin and pan-class I\/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma","volume":"122","author":"Amengual","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2021051715324302100_B15","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.18632\/oncotarget.14876","article-title":"Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma","volume":"8","author":"Mondello","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2021051715324302100_B16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41419-019-2210-0","article-title":"Novel HDAC inhibitor chidamide synergizes with rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20","volume":"11","author":"Guan","year":"2020","journal-title":"Cell Death Dis"},{"issue":"10 pt 1","key":"2021051715324302100_B17","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2021051715324302100_B18","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3109\/10428194.2015.1135431","article-title":"A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520","volume":"57","author":"Puvvada","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2021051715324302100_B19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"2021051715324302100_B20","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1080\/10428194.2017.1298751","article-title":"A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas","volume":"58","author":"Sborov","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2021051715324302100_B21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/hon.2515","article-title":"Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study","volume":"36","author":"Barnes","year":"2018","journal-title":"Hematol Oncol"},{"issue":"12","key":"2021051715324302100_B22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/bloodadvances.2018019240","article-title":"Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)","volume":"2","author":"Drott","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2021051715324302100_B23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ajh.25010","article-title":"A phase I\/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806","volume":"93","author":"Persky","year":"2018","journal-title":"Am J Hematol"},{"issue":"9","key":"2021051715324302100_B24","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021051715324302100_B25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"2021051715324302100_B26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Chen","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"2021051715324302100_B27","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"2021051715324302100_B28","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1535-7163.MCT-09-0689","article-title":"SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer","volume":"9","author":"Novotny-Diermayr","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"2021051715324302100_B29","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1021\/jm2003552","article-title":"Discovery of (2E)-3-2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile","volume":"54","author":"Wang","year":"2011","journal-title":"J Med Chem"},{"issue":"5","key":"2021051715324302100_B30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bjc.2011.13","article-title":"Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours","volume":"104","author":"Razak","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"2021051715324302100_B31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdv033","article-title":"A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent\/metastatic sarcomas-NCIC-CTG IND 200","volume":"26","author":"Chu","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"2021051715324302100_B32","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.leukres.2012.03.003","article-title":"Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis","volume":"36","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Leuk Res"},{"issue":"11","key":"2021051715324302100_B33","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/pbc.24694","article-title":"A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program\/C17 pediatric phase I consortium","volume":"60","author":"Zorzi","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"24","key":"2021051715324302100_B34","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1002\/cncr.30949","article-title":"Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies","volume":"123","author":"Abaza","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"2021051715324302100_B35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/bloodadvances.2018027409","article-title":"Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study","volume":"3","author":"Garcia-Manero","year":"2019","journal-title":"Blood Adv"},{"issue":"15","key":"2021051715324302100_B36","article-title":"Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high\/very high-risk myelodysplastic syndromes [abstract]","volume":"38","author":"Atallah","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021051715324302100_B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125924","article-title":"A phase 3 randomized study (PRIMULA) of the epigenetic combination of pracinostat, a pan-histone deacetylase (HDAC) inhibitor, with azacitidine (AZA) in patients with newly diagnosed acute myeloid leukemia (AML) unfit for standard intensive chemotherapy (IC) [abstract]","volume":"134","author":"Garcia-Manero","year":"2019","journal-title":"Blood"},{"key":"2021051715324302100_B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123237","article-title":"Phase I study of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed\/refractory acute myeloid leukemia (AML) [abstract]","volume":"134","author":"Badar","year":"2019","journal-title":"Blood"},{"issue":"16","key":"2021051715324302100_B39","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1158\/1078-0432.CCR-18-2718","article-title":"The ETS inhibitors YK-4-279 and TK-216 are novel antilymphoma agents","volume":"25","author":"Spriano","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2021051715324302100_B40","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.3324\/haematol.2019.227215","article-title":"Targeting CD205 with the antibody drug conjugate MEN1309\/OBT076 is an active new therapeutic strategy in lymphoma models","volume":"105","author":"Gaudio","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"2021051715324302100_B41","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021051715324302100_B42","doi-asserted-by":"crossref","article-title":"gplots: Various R Programming Tools for Plotting Data","author":"Warnes","DOI":"10.32614\/CRAN.package.gplots"},{"issue":"12","key":"2021051715324302100_B43","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.3324\/haematol.2018.214957","article-title":"Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses","volume":"104","author":"Cascione","year":"2019","journal-title":"Haematologica"},{"issue":"43","key":"2021051715324302100_B44","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2021051715324302100_B45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","article-title":"PQR309 is a novel dual PI3K\/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy","volume":"24","author":"Tarantelli","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2021051715324302100_B46","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"issue":"6769","key":"2021051715324302100_B47","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"5","key":"2021051715324302100_B48","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2021051715324302100_B49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"2021051715324302100_B50","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ding","year":"2008","journal-title":"Blood"},{"issue":"24","key":"2021051715324302100_B51","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1182\/blood-2016-03-705814","article-title":"An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL","volume":"128","author":"Mai","year":"2016","journal-title":"Blood"},{"key":"2021051715324302100_B52","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10637-010-9596-y","article-title":"Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect","volume":"28","author":"Dickinson","year":"2010","journal-title":"Invest New Drugs"},{"issue":"4","key":"2021051715324302100_B53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","article-title":"Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma","volume":"22","author":"Caro","year":"2012","journal-title":"Cancer Cell"},{"issue":"11","key":"2021051715324302100_B54","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1073\/pnas.76.11.5606","article-title":"Glutathione: interorgan translocation, turnover, and metabolism","volume":"76","author":"Griffith","year":"1979","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2021051715324302100_B55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/JCO.1994.12.1.194","article-title":"Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione","volume":"12","author":"Bailey","year":"1994","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021051715324302100_B56","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1200\/JCO.1996.14.1.249","article-title":"Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer","volume":"14","author":"O\u2019Dwyer","year":"1996","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021051715324302100_B57","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2007-07-100115","article-title":"SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2021051715324302100_B58","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ccr.2013.05.002","article-title":"SYK inhibition modulates distinct PI3K\/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas","volume":"23","author":"Chen","year":"2013","journal-title":"Cancer Cell"},{"issue":"2","key":"2021051715324302100_B59","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/cdd.2016.116","article-title":"Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets","volume":"24","author":"Norberg","year":"2017","journal-title":"Cell Death Differ"},{"issue":"24","key":"2021051715324302100_B60","doi-asserted-by":"crossref","first-page":"e00328","DOI":"10.1128\/MCB.00328-17","article-title":"Effect of mutant p53 proteins on glycolysis and mitochondrial metabolism","volume":"37","author":"Eriksson","year":"2017","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2021051715324302100_B61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ccell.2018.12.012","article-title":"Wild-type p53 promotes cancer metabolic switch by inducing PUMA-dependent suppression of oxidative phosphorylation","volume":"35","author":"Kim","year":"2019","journal-title":"Cancer Cell"},{"issue":"4","key":"2021051715324302100_B62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jmcb\/mjz010","article-title":"Understanding p53 functions through p53 antibodies","volume":"11","author":"Sabapathy","year":"2019","journal-title":"J Mol Cell Biol"},{"issue":"1","key":"2021051715324302100_B63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/cancers11010004","article-title":"Regulators of oncogenic mutant TP53 gain of function","volume":"11","author":"Yamamoto","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2021051715324302100_B64","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1002\/jcp.28091","article-title":"The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML","volume":"234","author":"Nguyen","year":"2019","journal-title":"J Cell Physiol"},{"issue":"12","key":"2021051715324302100_B65","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"2021051715324302100_B66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: the bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp Mol Med"},{"issue":"7","key":"2021051715324302100_B67","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cancers11070916","article-title":"Exploiting mitochondrial vulnerabilities to trigger apoptosis selectively in cancer cells","volume":"11","author":"Nguyen","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2021051715324302100_B68","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/10\/2467\/1807434\/advancesadv2020003566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/10\/2467\/1807434\/advancesadv2020003566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:41:41Z","timestamp":1725064901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/10\/2467\/475947\/Study-of-the-antilymphoma-activity-of-pracinostat"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,5,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003566","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]}}}